Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.

Vaikari VP, Du Y, Wu S, Zhang T, Metzeler K, Batcha AMN, Herold T, Hiddemann W, Akhtari M, Alachkar H.

Haematologica. 2019 Aug 1. pii: haematol.2018.207001. doi: 10.3324/haematol.2018.207001. [Epub ahead of print]

2.

CD97 expression is associated with poor overall survival in acute myeloid leukemia.

Vaikari VP, Yang J, Wu S, Alachkar H.

Exp Hematol. 2019 Jul;75:64-73.e4. doi: 10.1016/j.exphem.2019.06.474. Epub 2019 Jun 29.

PMID:
31260716
3.

Characterization of upregulated adhesion GPCRs in acute myeloid leukemia.

Yang J, Wu S, Alachkar H.

Transl Res. 2019 May 17. pii: S1931-5244(19)30098-2. doi: 10.1016/j.trsl.2019.05.004. [Epub ahead of print]

PMID:
31153896
4.

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia.

Gutierrez L, Jang M, Zhang T, Akhtari M, Alachkar H.

Sci Rep. 2018 Dec 3;8(1):17544. doi: 10.1038/s41598-018-35978-0.

5.

Clinical and laboratory features of seventy-eight UK patients with Good's syndrome (thymoma and hypogammaglobulinaemia).

Zaman M, Huissoon A, Buckland M, Patel S, Alachkar H, Edgar JD, Thomas M, Arumugakani G, Baxendale H, Burns S, Williams AP, Jolles S, Herriot R, Sargur RB, Arkwright PD.

Clin Exp Immunol. 2019 Jan;195(1):132-138. doi: 10.1111/cei.13216. Epub 2018 Oct 21.

6.

Characterization of Mutations in the Mitochondrial Encoded Electron Transport Chain Complexes in Acute Myeloid Leukemia.

Wu S, Akhtari M, Alachkar H.

Sci Rep. 2018 Sep 5;8(1):13301. doi: 10.1038/s41598-018-31489-0.

7.

Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.

Dorjbal B, Stinson JR, Ma CA, Weinreich MA, Miraghazadeh B, Hartberger JM, Frey-Jakobs S, Weidinger S, Moebus L, Franke A, Schäffer AA, Bulashevska A, Fuchs S, Ehl S, Limaye S, Arkwright PD, Briggs TA, Langley C, Bethune C, Whyte AF, Alachkar H, Nejentsev S, DiMaggio T, Nelson CG, Stone KD, Nason M, Brittain EH, Oler AJ, Veltri DP, Leahy TR, Conlon N, Poli MC, Borzutzky A, Cohen JI, Davis J, Lambert MP, Romberg N, Sullivan KE, Paris K, Freeman AF, Lucas L, Chandrakasan S, Savic S, Hambleton S, Patel SY, Jordan MB, Theos A, Lebensburger J, Atkinson TP, Torgerson TR, Chinn IK, Milner JD, Grimbacher B, Cook MC, Snow AL.

J Allergy Clin Immunol. 2019 Apr;143(4):1482-1495. doi: 10.1016/j.jaci.2018.08.013. Epub 2018 Aug 28.

PMID:
30170123
8.

Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia.

Wu S, Du Y, Beckford J, Alachkar H.

J Transl Med. 2018 Jun 20;16(1):170. doi: 10.1186/s12967-018-1539-y.

9.

The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017.

Shillitoe B, Bangs C, Guzman D, Gennery AR, Longhurst HJ, Slatter M, Edgar DM, Thomas M, Worth A, Huissoon A, Arkwright PD, Jolles S, Bourne H, Alachkar H, Savic S, Kumararatne DS, Patel S, Baxendale H, Noorani S, Yong PFK, Waruiru C, Pavaladurai V, Kelleher P, Herriot R, Bernatonienne J, Bhole M, Steele C, Hayman G, Richter A, Gompels M, Chopra C, Garcez T, Buckland M.

Clin Exp Immunol. 2018 Jun;192(3):284-291. doi: 10.1111/cei.13125.

10.

The era of immunogenomics/immunopharmacogenomics.

Zewde M, Kiyotani K, Park JH, Fang H, Yap KL, Yew PY, Alachkar H, Kato T, Mai TH, Ikeda Y, Matsuda T, Liu X, Ren L, Deng B, Harada M, Nakamura Y.

J Hum Genet. 2018 Jul;63(8):865-875. doi: 10.1038/s10038-018-0468-1. Epub 2018 May 21. Review.

PMID:
29785006
11.

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.

Griffin LL, Cove-Smith L, Alachkar H, Radford JA, Brooke R, Linton KM.

JAAD Case Rep. 2018 Feb 23;4(3):229-231. doi: 10.1016/j.jdcr.2017.09.028. eCollection 2018 Apr. No abstract available.

12.

Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy.

Stubbs A, Bangs C, Shillitoe B, Edgar JD, Burns SO, Thomas M, Alachkar H, Buckland M, McDermott E, Arumugakani G, Jolles S, Herriot R, Arkwright PD.

Clin Exp Immunol. 2018 Feb;191(2):212-219. doi: 10.1111/cei.13068. Epub 2017 Nov 3. Erratum in: Clin Exp Immunol. 2018 Jun;192(3):377. Jolles, M S [corrected to Jolles, S].

13.

Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection.

Alachkar H, Mutonga M, Kato T, Kalluri S, Kakuta Y, Uemura M, Imamura R, Nonomura N, Vujjini V, Alasfar S, Rabb H, Nakamura Y, Alachkar N.

BMC Nephrol. 2016 Nov 21;17(1):181.

14.

Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.

Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, Larson RA, Bloomfield CD, Marcucci G, Nakamura Y, Stock W.

Pharmacogenomics J. 2017 Jun;17(3):274-279. doi: 10.1038/tpj.2016.7. Epub 2016 Mar 29.

15.

Deep-sequencing of the T-cell receptor repertoire in patients with haplo-cord and matched-donor transplants.

Alachkar H, Nakamura Y.

Chimerism. 2015 Jul 3;6(3):47-9. doi: 10.1080/19381956.2015.1128624. Epub 2016 Jan 8.

16.

Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia.

Brent J, Guzman D, Bangs C, Grimbacher B, Fayolle C, Huissoon A, Bethune C, Thomas M, Patel S, Jolles S, Alachkar H, Kumaratne D, Baxendale H, Edgar JD, Helbert M, Hambleton S, Arkwright PD.

Clin Exp Immunol. 2016 Apr;184(1):73-82. doi: 10.1111/cei.12748. Epub 2016 Jan 27.

17.

Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis.

Hamilton P, Ogundare O, Raza A, Ponnusamy A, Gorton J, Alachkar H, Choudhury J, Barratt J, Kalra PA.

Case Rep Nephrol. 2015;2015:269895. doi: 10.1155/2015/269895. Epub 2015 Nov 3.

18.

SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells.

Vougiouklakis T, Sone K, Saloura V, Cho HS, Suzuki T, Dohmae N, Alachkar H, Nakamura Y, Hamamoto R.

Oncotarget. 2015 Dec 22;6(41):43162-71. doi: 10.18632/oncotarget.6351.

19.

Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis.

Kosmidis C, Powell G, Borrow R, Morris J, Alachkar H, Denning DW.

Vaccine. 2015 Dec 16;33(51):7271-7275. doi: 10.1016/j.vaccine.2015.10.114. Epub 2015 Nov 3.

PMID:
26546263
20.

Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).

Mutonga M, Tamura K, Malnassy G, Fulton N, de Albuquerque A, Hamamoto R, Stock W, Nakamura Y, Alachkar H.

Transl Oncol. 2015 Oct;8(5):368-75. doi: 10.1016/j.tranon.2015.07.003.

21.

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.

Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y.

Oncotarget. 2015 Oct 20;6(32):33410-25. doi: 10.18632/oncotarget.5418.

22.

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.

Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y.

Bone Marrow Transplant. 2015 Sep;50(9):1227-34. doi: 10.1038/bmt.2015.133. Epub 2015 Jun 8.

23.

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G.

Leukemia. 2015 Oct;29(10):1981-92. doi: 10.1038/leu.2015.106. Epub 2015 May 14.

24.

Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe.

Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritterbusch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD.

J Clin Immunol. 2015 Feb;35(2):199-205. doi: 10.1007/s10875-015-0137-5. Epub 2015 Feb 8.

PMID:
25663093
25.

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.

Alachkar H, Mutonga MB, Metzeler KH, Fulton N, Malnassy G, Herold T, Spiekermann K, Bohlander SK, Hiddemann W, Matsuo Y, Stock W, Nakamura Y.

Oncotarget. 2014 Dec 15;5(23):12371-82.

26.

TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.

Matsuo Y, Park JH, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, Nakamura Y.

Sci Transl Med. 2014 Oct 22;6(259):259ra145. doi: 10.1126/scitranslmed.3010277.

27.

WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.

Saloura V, Cho HS, Kiyotani K, Alachkar H, Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M, Licht J, Nakamura Y, Hamamoto R.

Mol Cancer Res. 2015 Feb;13(2):293-304. doi: 10.1158/1541-7786.MCR-14-0292-T. Epub 2014 Oct 3.

28.

Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke.

Hurford R, Rezvani S, Kreimei M, Herbert A, Vail A, Parry-Jones AR, Douglass C, Molloy J, Alachkar H, Tyrrell PJ, Smith CJ.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):520-3. doi: 10.1136/jnnp-2014-308097. Epub 2014 Jul 12.

PMID:
25016564
29.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.

J Clin Invest. 2014 Apr;124(4):1512-24. doi: 10.1172/JCI70921. Epub 2014 Mar 3.

30.

Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation.

Arkwright PD, Riley P, Hughes SM, Alachkar H, Wynn RF.

J Allergy Clin Immunol. 2014 Jan;133(1):265-7. doi: 10.1016/j.jaci.2013.07.035. Epub 2013 Sep 12. No abstract available.

PMID:
24035158
31.

The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012.

Edgar JD, Buckland M, Guzman D, Conlon NP, Knerr V, Bangs C, Reiser V, Panahloo Z, Workman S, Slatter M, Gennery AR, Davies EG, Allwood Z, Arkwright PD, Helbert M, Longhurst HJ, Grigoriadou S, Devlin LA, Huissoon A, Krishna MT, Hackett S, Kumararatne DS, Condliffe AM, Baxendale H, Henderson K, Bethune C, Symons C, Wood P, Ford K, Patel S, Jain R, Jolles S, El-Shanawany T, Alachkar H, Herwadkar A, Sargur R, Shrimpton A, Hayman G, Abuzakouk M, Spickett G, Darroch CJ, Paulus S, Marshall SE, McDermott EM, Heath PT, Herriot R, Noorani S, Turner M, Khan S, Grimbacher B.

Clin Exp Immunol. 2014 Jan;175(1):68-78. doi: 10.1111/cei.12172.

32.

A UK national audit of hereditary and acquired angioedema.

Jolles S, Williams P, Carne E, Mian H, Huissoon A, Wong G, Hackett S, Lortan J, Platts V, Longhurst H, Grigoriadou S, Dempster J, Deacock S, Khan S, Darroch J, Simon C, Thomas M, Pavaladurai V, Alachkar H, Herwadkar A, Abinun M, Arkwright P, Tarzi M, Helbert M, Bangs C, Pastacaldi C, Phillips C, Bennett H, El-Shanawany T.

Clin Exp Immunol. 2014 Jan;175(1):59-67. doi: 10.1111/cei.12159.

33.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

34.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G.

Blood. 2013 Jan 3;121(1):159-69. doi: 10.1182/blood-2012-05-428573. Epub 2012 Oct 25.

35.

Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.

Alachkar H, Xie Z, Marcucci G, Chan KK.

J Pharm Biomed Anal. 2012 Dec;71:228-32. doi: 10.1016/j.jpba.2012.08.011. Epub 2012 Aug 19.

36.

Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms.

Smith RM, Alachkar H, Papp AC, Wang D, Mash DC, Wang JC, Bierut LJ, Sadee W.

Eur J Hum Genet. 2011 Jan;19(1):76-83. doi: 10.1038/ejhg.2010.120. Epub 2010 Aug 11.

37.

Allelic mRNA expression of sortilin-1 (SORL1) mRNA in Alzheimer's autopsy brain tissues.

Alachkar H, Kataki M, Scharre DW, Papp A, Sadee W.

Neurosci Lett. 2008 Dec 19;448(1):120-4. doi: 10.1016/j.neulet.2008.10.034. Epub 2008 Oct 15.

38.

Meningococcal meningitis in a patient with urticarial vasculitis: is there a link?

Alachkar H, Qasim F, Ahmad Y, Helbert M.

J Clin Pathol. 2007 Oct;60(10):1160-1. No abstract available.

39.

Skin penetration and lag times of neat and aqueous diethyl phthalate, 1,2-dichloroethane and naphthalene.

Frasch HF, Barbero AM, Alachkar H, McDougal JN.

Cutan Ocul Toxicol. 2007;26(2):147-60.

PMID:
17612981
40.

Supplemental Content

Loading ...
Support Center